We assessed the relationship between different intermediate criteria and overall survival (OS) in metastatic colorectal cancer patients who received first-line chemotherapy with bevacizumab. Duration of disease control and time to failure of strategy were strongly correlated with OS, which makes them relevant as intermediate criteria in future clinical trials. Background: We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab. Patients and Methods: We assessed OS, progression-free survival (PFS), duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), which was defined as the entire period before the introduction of a second-line treatment. Linear correlation and regression models were used, and Prentice criteria were investigated. Results: With a median follow-up of 57.6 months for 216 patients, the median OS was 24. 
Introduction
First-line chemotherapy is often administered to patients with metastatic colorectal cancer (mCRC) until disease progression or unacceptable toxicity, particularly for the folinic acid-fluorouracilirinotecan (FOLIRI)-bevacizumab scheme. 1 The current maintenance strategy is a first-line treatment option and consists of a reduction in the chemotherapy dose intensity to maintain disease control. 2 Recent trials allocated patients after 3 to 6 months of induction treatment to different maintenance strategies and/or observation alone. [3] [4] [5] [6] [7] [8] [9] These trials all showed an effect on progression-free survival (PFS) or the respective alternate endpoints (eg, "time to failure of strategy" [TFS] or "duration of disease control" [DDC] ); however, the correlation between these endpoints and overall survival (OS), the most clinically relevant endpoint in phase III trials, remains unclear. A meta-analysis was performed to compare observation alone, bevacizumab, or bevacizumab and chemotherapy maintenance after induction chemotherapy in terms of PFS and OS. The results from the meta-analysis clearly showed significant benefits in terms of PFS and a trend toward prolonged OS in favor of a bevacizumab-based maintenance compared with observation alone after 3 to 6 months of induction treatment. 10 In a first meta-analysis on the basis of the individual data of 1000 patients from 3 randomized trials of maintenance strategy, C97-3, 11 OPTIMOX 1, 12 and OPTIMOX 2, 3 Chibaudel and colleagues established TFS and DDC as alternative composite endpoints. Specifically, the authors showed a better surrogacy for TFS and DDC to OS compared with PFS. 13 However, individual data collected by Chibaudel and colleagues mainly concerned protocols without targeted therapies (FOLFIRI, folinic acid, fluorouracil and oxaliplatin (FOLFOX), and folinic acid, fluorouracil (LV5FU2)), and the utility of these criteria in clinical trials has been controversial in the literature. Thus, PFS was not a surrogate for OS because the correlation between PFS and OS was modest (R 2 , 0.45-0.69) in 22 modern trials of first-line therapy for mCRC analyzing individual patient data. 14 We need more data on the effectiveness of these criteria in targeted therapy-based schemes. Maintenance schemes have reinforced the idea that PFS is not necessarily the best OS surrogate endpoint because subsequent lines might bias it.
In addition, the endpoint of PFS was considered to have a high potential for bias because of the open-label design of the 3 studies (ie, CAIRO3, 5 SAKK 41/06, 9 and AIO 0207 6 ). In these studies, the radiologic images were not centrally assessed; they were assessed at the study sites. Furthermore, patients received a less intensive regimen with a more favorable toxicity profile in maintenance approaches. 15 The significance of clinical benefit in patient assessment requires the use of validated surrogate endpoints to OS and health-related quality of life in modern clinical trials. In this study, our first aim was to assess the relationship between different intermediate criteria (PFS, DDC, and TFS) and OS in a large cohort of patients who received a first-line chemotherapy associated with bevacizumab, thus potentially eligible for a maintenance strategy.
Patients and Methods
We collected retrospective data from patients with mCRC treated with first-line chemotherapy with bevacizumab between January 2006 and December 2012.
The study was performed at 2 general and 4 academic French hospitals. The inclusion criteria were as follows: age older than 18 years, no upper age limit, histologically proven mCRC, and metastases occurring immediately or secondarily after a curative strategy. Patients were included regardless of previous surgery, primary tumor resection, or Kirsten rat sarcoma (KRAS) mutational status. Included patients received treatment on the basis of mono-, bi-, or trichemotherapy with additional use of bevacizumab, and subsequent lines were selected by the physician.
We assessed the following endpoints: OS, time between the first treatment administration and death from all causes considered; PFS, time between the first treatment administration and the first established progression; TFS, the entire period before the introduction of second-line treatment and DDC, the sum of the periods in which the disease did not progress (ie, the sum of PFS of each active treatment course). DDC excluded the following: intervals between disease progression and the reinitiation of treatment and the PFS of inactive treatment if progressive disease had occurred at the first evaluation after treatment reinitiation (either reintroduction into a stop-and-go strategy or a subsequent course of treatment in multiline strategy; Figure 1 ).
The median time-to-event endpoints and the 95% confidence intervals (CIs) were estimated using the KaplaneMeier method. The survival curves were compared using the log rank test. The reverse KaplaneMeier method was used to calculate median follow-up. Factors associated with the OS, PFS, DDC, or TFS were investigated using univariate and multivariate Cox models. The proportional hazard assumption was graphically assessed. To study endpoint correlation, OS, DDC, and TFS were transformed by the cube root to meet the conditions required by the linear correlation model. Linear correlation and linear regression models were used to study the relationships between OS and TFS or DDC. The coefficient of determination, R 2 , was computed for each model. An R 2 > 0.75 is considered an indicator of strong model adequacy. The CIs at 95% were estimated for each R 2 using the resampling bootstrap method.
Univariate and multivariate Cox models were performed considering the resection of metastases as the treatment. Variables associated with the considered endpoint less than a P value of .20 in univariate Cox models were introduced in multivariate models, and a backward selection process was applied. The Prentice criteria were then studied. Specifically, Prentice and others 16, 17 proposed a definition of the substitution criteria, divided into 4 operational criteria, and we sought to verify these criteria as follows:
The treatment effect on the surrogate endpoint was significant. The treatment effect on the final endpoint was significant. The surrogate significantly affected prognosis. After adjusting the surrogate endpoint, the effect of treatment on the final endpoint was no longer significant: the surrogate completely captured the effect of treatment.
All analyses were performed with SAS software version 9.3 (SAS Institute Inc, Cary, NC) at an a level of 5% with bilateral tests.
Results

Description of the Population
Two hundred sixteen patients were included as follows: 118 (54.6%) men and 98 (45.4%) women. The median age was 60.0 years (range, 24.1-80.9), and all patients had a World Health Organization status of 2.
Primary tumors were predominantly classified as locally advanced colorectal cancer as follows: T3 for 92 patients (42.6%), T4 for 48 patients (22.2%), N1 for 44 patients (20.4%), and N2 for 58 patients (26.9%). One hundred thirty-eight patients (63.9%) had synchronous metastases. Seventy-nine patients (38.7%) received chemotherapy with curative intent (neoadjuvant or adjuvant). Of the patients who had developed metastases, 169 patients (78.2%) had at least 2 metastatic sites other than lymph nodes. The most represented visceral metastatic site was the liver, which harbored metastases in 168 patients (77.8%), followed by the lung in 90 patients (41.7%), and peritoneal carcinomatosis in 50 patients (23.2%).
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Alternative Endpoints in CRC First-Line Bevacizumab One hundred sixty-two patients (75%) were receiving treatment for the primary tumor before starting first-line chemotherapy, and 159 (73.6%) patients underwent surgery.
The first-line metastatic schemes consisted of FOLFIRIbevacizumab for 149 patients (69.0%) and FOLFOX-bevacizumab for 50 patients (23.2%). The other first-line therapies were represented to a lesser extent as follows: LV5FU2-bevacizumab, capecitabine-irinotecan-bevacizumab, and capecitabine-oxaliplatinbevacizumab were administered to 6 (2.8%), 6 (2.8%), and 4 (1.8%) patients, respectively. Only 1 patient (0.46%) received 5FU-folinic acid-oxaliplatin-irinotecan (FOLFOXIRI)-bevacizumab. Anti-epidermal growth factor receptor (EGFR) was administered in subsequent lines to 79 patients (36.6%).
The number of lines of therapy ranged from 1 to 7. Specifically, 44 (20.4%), 67 (31.0%), and 105 (48.6%) patients received 1, 2, and 3 lines of therapy, respectively. The median number of lines of therapy was 2 (interquartile range, 2-4).
Metastases were resected in 81 patients (37.7%), of whom 44 (20.4%) underwent resection during first-line therapy. Ninety-one patients (42.1%) were able to resume chemotherapy with bevacizumab beyond a dose-reduction leading to disease progression (Table 1) .
After a median follow-up of 52.3 months (range, 0.3-94.0), the median OS was 24.5 (95% CI, 21.3-29.7; range, 0.3-94.0) months, the median PFS was 8.9 months (95% CI, 8.4-9.7; range, 0.3-46.5) months, the median DDC was 11.0 months (95% CI, 9.8-12.4; range, 0.3-77.8), and the median TFS was 11.1 (95% CI, 10.0-13.0; range, 0.3-77.8) months (Figure 2 ). At the end of the follow-up, 171 patients (79.2%) had died, and all patients had experienced progression.
Relationship Between Candidate Alternative Endpoints and OS
The cube root transformation provided distributions satisfying the conditions of normality and homoscedasticity for OS, DDC, and TFS, but not for PFS.
The correlation between OS and DDC was relatively strong, with a Pearson coefficient of 0.79 (95% CI, 0.73-0.83). A linear regression analysis showed a significant association between OS and DDC, and this relationship can be modeled using the following formula: cubic root (OS) ¼ 0.9547 þ 0.8286 cubic root (DDC) ( Figure 3A) .
With a coefficient of determination of 0.62 (95% CI, 0.54-0.70), the strength of the correlation was average.
The correlation between OS and TFS was relatively strong, with a Pearson coefficient of 0.79 (95% CI, 0.73-0.84). A linear regression analysis showed a significant association between OS and DDC, and this relationship can be modeled using the following formula: cubic root (OS) ¼ 0.9655 þ 0.8186 cubic root (TFS) ( Figure 3B ).
With a coefficient of determination of 0.63 (95% CI, 0.54-0.71), the strength of the correlation was average. 
Application of Prentice Criteria
Relationship Between OS and DDC. Using multivariate Cox models, we have shown the following, considering metastases resection as the treatment to be evaluated:
A significant association between metastases resection and OS (Table 2) . A significant association between metastases resection and DDC (Table 3) . Moreover, DDC and OS were strongly correlated ( Figure 3A) . After the introduction of the DDC variable into the final multivariate model of the OS, the resection of metastases was no longer significantly associated with OS (see Supplemental Table 1 in the online version).
The 4 Prentice criteria were respected for DDC.
Regarding the Relationship Between OS and TFS. Using multivariate Cox models, we have shown the following, considering metastases resection as the treatment to be evaluated: A significant association between metastases resection and TFS (Table 4) . A significant association between metastases resection and OS (Table 2) . Moreover, TFS and OS strongly correlated ( Figure 3B ). After the introduction of the TFS variable into the final multivariate model of the OS, the resection of metastases was no longer significantly associated with OS (see Supplemental Table 2 in the online version).
The four Prentice criteria were respected for TFS.
Discussion
We showed a significant correlation between the alternative endpoints TFS and DDC, assessing the response before and after progression, and OS. Alternative Endpoints in CRC First-Line Bevacizumab
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Progression-free survival could not be studied as an intermediate endpoint because a transformation that satisfied the conditions of normality and homoscedasticity was not found.
The meta-analysis of Chibaudel and colleagues showed the best TFSeOS correlation (adjusted coefficient R 2 ¼ 0.67) and
with PFS, and the correlations of these 2 criteria with OS did not differ. 13 The application of the Prentice criteria proved the clinical validity of these alternative endpoints. We considered metastatic resection as the criterion to be evaluated in the Prentice method because it was the best strategy in case of not immediately resectable mCRC. 18 and quality of life 19 and allows planned sequence induction. Only 91 patients (42%) received a reinduction of initial protocol after de-escalation in our cohort, which is almost identical to the reinduction rate of the AIO 0207 cohort (36%) 6 and CAIRO 3 (47%) study for the capecitabine-bevacizumab arm. 5 In the CAIRO 3 study, the primary endpoint, PFS after first progression requiring capécitabine-oxaliplatine (CAPOX) reintroduction, was significantly increased in the maintenance arm (11.7 months vs. 8. . Moreover, TFS and DDC permitted assessment before and after the first cancer progression. Therefore, this alternative endpoint is preferable for a maintenance strategy. The Alternative Endpoints in CRC First-Line Bevacizumab
FIRE 3 trial has shown a significant difference in the OS, but not PFS, 21 in favor of the FOLFIRI with cetuximab scheme, but OS was not the primary outcome. The value of PFS as an appropriate surrogate parameter for OS was questioned when the OS exceeds 30 months, whereas the first-line PFS is approximately 10 months in many studies. With the introduction of biological agents and the availability of several lines of treatment, this formerly strong association has become weaker. 22 In other locations, maintenance strategies have been established because of phase III trials that reached their main objective-PFS. For example, erlotinib 23 or bevacizumab have shown efficacy in the AVAPERL trial against nonesmall-cell lung cancer. 24 Bevacizumab also improved the PFS of patients with ovarian cancer after a carboplatin-paclitaxel protocol in the GOG 218 25 and ICON 7 26 trials, without the need to use colorectal cancer surrogate endpoints. Our study presents several limitations because of the "old" period of inclusion (ie, January 2006 to December 2012). Most patients had FOLFIRI-bevacizumab as induction treatment whereas oxaliplatin-based CAPOX-bevacizumab or FOLFOX-bevacizumab are nowadays more validated in the literature. Furthermore, the heterogeneities in the treatment applied (eg, differences in the induction treatment and fluoropyrimidine maintenance schedule, which depend on the study site) should be considered but represented the real-life practice in first-line treatment. Published induction treatments were heterogeneous among trials in terms of duration, ranging from 3 to 6 months, the use of oxaliplatin (100% of patients in CAIRO 3 and AIO KRK 0207, 62% in SAKK 41/06, with 31% receiving irinotecan), intensity (7% received induction treatment with fluoropyrimidine and bevacizumab in the SAKK 41/06), and the fluoropyrimidine backbone used (capecitabine/oxaliplatin at 100% in CAIRO3 and only 16% in AIO KRK 0207). 10 Ongoing trials are using alternative endpoints, such as DDC in the STRATEGIC GERCOR-1 study, an open-label, randomized, multicenter, phase III trial that aims to determine the optimal treatment sequence in wild type RAS patients receiving anti-EGFR-irinotecan and OPTIMOXbevacizumab schedules. 27 Other personalized studies exploring the activity of novel drugs in molecularly defined subgroups have already been started, most notably the FOCUS4 28 and MODUL 29 trials, with different endpoints. MODUL uses coprimary endpoints, such as early efficacy, defined as the proportion of patients with a 20% reduction in tumor size after 2 months of maintenance treatment, and PFS. The early tumor shrinkage defined by a 20% reduction in the sum of the longest diameters of target lesions was identified as the optimal cutoff to discriminate early responders versus nonearly responders. Early tumor shrinkage and depth of response as predictors of OS were confirmed in a chemotherapy in the phase III TRIBE trial of FOLFOXIRI with bevacizumab versus FOLFIRI with bevacizumab 30 and also appeared as clinically relevant endpoints in future clinical trials. Moreover, the surrogacy of early tumor shrinkage is being evaluated into the Aide et Recherche en Cancérologie Digestive (ARCAD) database program. 31 
Conclusion
Duration of disease control and TFS are clinically relevant alternative endpoints that retrospectively correlate with OS in a large cohort of patients with mCRC treated with a bevacizumabassociated schedule as first-line therapy. They might be preferentially used as primary endpoints in future clinical trials instead of PFS, but a meta-analysis of pooled randomized trials is warranted.
Clinical Practice Points
Maintenance strategy exists despite limited evidence in the literature. The PFS endpoint was considered to have a high potential for bias. DDC and TFS are alternative endpoints to OS, whose usefulness is still debated in the literature. In our study, DDC and TFS correlated to OS and Prentice criteria were verified retrospectively in a large cohort of "potentially eligible" patients to a maintenance strategy, initially treated with chemotherapy associated with bevacizumab. This is a supplemental argument to consider DDC and TFS as clinically relevant in current and future clinical trials. Nevertheless, DDC and TFS also could be biased and a metaanalysis of pooled randomized trials is warranted. 
